Specialty Pharmacy Medications in PI Cases: Attorney Guide

James Wong — Founder & Pharmacist, LienScripts | March 29, 2026 | 7 min read

Specialty pharmacy medications — biologics, infusions, and high-cost oral drugs — are increasingly relevant in personal injury cases involving severe or treatment-resistant conditions. When a PI patient requires specialty pharmacy access, the case has moved beyond routine treatment into a category that demands specific pharmacy lien infrastructure and cost justification strategy.

Specialty pharmacy medications are drugs that require special handling, administration, or monitoring beyond what a standard retail pharmacy provides. In personal injury cases, specialty medications appear when the patient's injuries produce conditions that standard oral medications cannot adequately treat — post-traumatic migraine requiring CGRP monoclonals, severe neuropathic pain requiring specialty compounding, or complex post-surgical recovery requiring biologic wound-healing agents.

• Specialty pharmacy medications include biologics (CGRP monoclonal antibodies, TNF inhibitors), infusion therapies, high-cost oral drugs requiring REMS programs, and specialty compounds
• These medications typically cost thousands per month and require cold-chain storage, patient monitoring programs, and specialized dispensing infrastructure
• In PI cases, specialty medications document treatment-resistant injury that has progressed beyond standard first-line therapy
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that captures specialty medication dispensing with clinical rationale, storage chain documentation, and cost justification
• Pharmacy lien coverage eliminates the prior authorization barriers that frequently delay or deny specialty medication access for injured patients

What Makes a Medication "Specialty"

The specialty pharmacy designation is not arbitrary. Medications qualify as specialty based on one or more of the following characteristics:

Biologic origin. Biologics are produced from living organisms rather than chemical synthesis. Their molecular complexity requires specialized manufacturing, cold-chain distribution, and careful handling. CGRP monoclonal antibodies (Aimovig, Ajovy, Emgality) and TNF inhibitors (Humira, Enbrel) are common examples in PI-adjacent prescribing.

Special storage requirements. Many specialty medications require refrigeration (2-8°C) from manufacturing through patient administration. Any break in the cold chain renders the medication potentially unsafe. The pharmacy must maintain and document temperature-controlled storage.

REMS programs. Some specialty medications operate under FDA Risk Evaluation and Mitigation Strategies that impose prescriber certification, patient registration, and dispensing restrictions. These programs exist for drugs with serious safety profiles that require active risk management.

Patient monitoring requirements. Specialty medications may require baseline lab work, ongoing monitoring (liver function, blood counts, infection screening), and structured follow-up that extends the pharmacist's clinical role beyond standard dispensing.

[!KEY] When a PI patient's treatment regimen includes specialty pharmacy medications, the case has moved beyond routine care. The specialty designation itself documents that the patient's condition requires advanced therapeutic intervention that standard retail pharmacy medications could not address — this is powerful evidence of injury severity.

Specialty Medications Commonly Seen in PI Cases

CGRP Monoclonal Antibodies

Erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti) for post-traumatic chronic migraine. These are the most frequently prescribed specialty medications in PI pharmacy records. Monthly self-injection or quarterly IV infusion. Prescribed after failure of oral preventive agents.

Specialty Pain Compounds

Complex compounded formulations combining multiple active ingredients (ketamine, gabapentin, baclofen, diclofenac, lidocaine) in topical or transdermal delivery systems. These require specialty compounding pharmacies with the capability to produce sterile or non-sterile compounds to specific formulations.

Post-Surgical Biologics

Growth factors, platelet-rich preparations, and biologic wound care products used in complex post-surgical recovery. These appear in PI cases involving major surgical repair of traumatic injuries.

Infusion Therapies

IV ketamine infusions for treatment-resistant chronic pain, IV lidocaine for neuropathic pain, and IV immunoglobulin for post-traumatic autoimmune conditions. Infusion therapy requires specialized administration and monitoring.

According to James Wong, PharmD, founder of LienScripts, "specialty medications in a PI pharmacy record are high-severity markers. Every one of them represents a clinical decision that standard therapy failed and the patient requires advanced treatment — that decision is itself evidence."

The Prior Authorization Problem

Specialty medications face the most aggressive prior authorization requirements in the insurance system. Health insurers impose step therapy protocols, clinical documentation requirements, and sometimes peer-to-peer review before authorizing specialty drugs. For PI patients, these barriers create specific problems:

Delay. Prior authorization for specialty medications can take weeks to months. A PI patient with post-traumatic migraine who needs Aimovig may wait 4-8 weeks for insurance authorization — during which their migraine goes untreated.

Denial. Insurers frequently deny specialty medication authorization, particularly for off-label uses or when the patient has not yet failed specific formulary alternatives. The denial may be clinically inappropriate but administratively final without appeal.

Step therapy requirements. Insurers may require the patient to fail two or three less costly oral medications before authorizing the specialty drug — even when the treating physician has clinical reasons to proceed directly to specialty therapy.

[!TIP] Pharmacy lien coverage bypasses the entire prior authorization apparatus. When LienScripts dispenses a specialty medication under lien, the prescribing physician's clinical judgment — not an insurer's formulary committee — determines the appropriate treatment. This eliminates weeks of delay and ensures the patient receives clinically indicated therapy promptly.

Cost Justification for Specialty Medications

Defense adjusters challenge specialty medication costs more aggressively than standard oral medication charges. The response requires specific preparation.

Clinical necessity chain. Document the sequence of failed oral medications that preceded the specialty prescription. The treating physician did not start with the most expensive option — they escalated to it after less costly alternatives proved inadequate.

FDA-approved indications. Confirm the specialty medication is prescribed for an FDA-approved or well-established off-label indication. CGRP monoclonals for chronic migraine have robust FDA approval and clinical trial data supporting their use.

Clinical outcomes documentation. When available, document the patient's clinical response to the specialty medication — reduced migraine frequency, improved function, return to activities. Therapeutic success justifies the cost.

Alternative cost comparison. Calculate the cumulative cost of the failed oral alternatives plus the cost of untreated disease (ER visits for breakthrough migraine, lost work days) versus the specialty medication cost. The specialty drug is often cost-effective when total healthcare utilization is considered.

[!KEY] The strongest defense of specialty medication charges is the clinical failure trail that precedes the prescription. An adjuster who sees three failed oral medications documented in the pharmacy record before the specialty drug was initiated has difficulty arguing the specialty medication was unnecessary.

LienScripts Specialty Medication Infrastructure

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "dispensing specialty medications under lien requires pharmacy infrastructure that most lien providers do not have — cold-chain storage with temperature monitoring, specialty inventory management, REMS program compliance, and clinical monitoring protocols. LienScripts maintains this infrastructure specifically because PI patients with the most serious injuries are the ones who need specialty access."

The MERIT report for cases involving specialty medications includes:

• Complete dispensing history with medication, dose, route, and administration schedule
• Storage chain documentation confirming proper handling
• Clinical rationale connecting the specialty medication to documented accident injuries
• Treatment escalation timeline showing prior oral medication failures
• Total specialty medication charges as a distinct section within the lien balance

When to Expect Specialty Medications in PI Cases

PI attorneys should anticipate specialty medication involvement in cases with:

• Post-traumatic chronic migraine (CGRP monoclonals)
• Severe neuropathic pain resistant to gabapentin and pregabalin (specialty compounds, infusions)
• Complex post-surgical recovery from major orthopedic or reconstructive surgery (biologic products)
• Treatment-resistant chronic pain syndromes (IV ketamine, specialty compounded topicals)
• Post-traumatic autoimmune or inflammatory conditions (biologic immunomodulators)

Early identification of potential specialty medication needs allows attorneys to ensure pharmacy lien coverage is in place before the prescriber writes the specialty prescription — preventing the delays and denials that insurance authorization would impose.

Related Resources

• CGRP Medications for Post-Traumatic Migraine
• Compound Medications in Personal Injury Cases
• Injectable Medications on Pharmacy Lien: Cost Strategy
• High-Value Pharmacy Demand Strategy